

expected to prevent an even broader spectrum of HPV-related cancers and other diseases and in particular, 90% of cervical cancers. This objective of this study was to estimate the incremental public health impact of a girls-only vaccination program with that of a universal vaccination program with a nonavalent human papillomavirus vaccine in Germany as compared to the current girls-only vaccination with a quadrivalent HPV vaccine (6/11/16/18). **METHODS:** A dynamic transmission model of HPV infection and the related diseases was calibrated to the German epidemiological data. Up to 70% of cervical cancer cases were attributed to HPV 16/18 for the quadrivalent vaccine, and an additional 20% to the five additional types included in the nonavalent vaccine. In the base case, a two dose vaccination program with lifelong protection and a cumulative vaccination coverage rate of 55.6% was assumed. Sensitivity analyses were conducted. **RESULTS:** The findings of the analyses indicate that girls-only vaccination with the nonavalent vaccine has the potential to: i) reduce the incidence of HPV16/18/31/33/45/52/58 -related cervical cancer by 73% after 100 years, relative to 57% for the quadrivalent vaccine and, ii) prevent an additional of 345,627 cases of CIN2/3 and 25,566 cases of cervical cancer over 100 years. When vaccination of girls with the nonavalent vaccine was extended to boys, the cumulative reduction over 100 years in the incident cases was 498,007 and 39,489 of CIN2/3 and cervical cancer respectively. **CONCLUSIONS:** The introduction of a nonavalent HPV vaccine immunization program in Germany is estimated to significantly reduce the public health impact of cervical and other HPV-related diseases.

**PCN186**  
**COST-EFFECTIVENESS AND FEASIBILITY OF IMPLEMENTING MRI-GUIDED**  
**NEOADJUVANT CHEMOTHERAPY TO TREAT ER-POSITIVE HER2-NEGATIVE**  
**BREAST CANCERS IN THE NETHERLANDS**

Miquel-Cases A<sup>1</sup>, Steuten L<sup>2</sup>, Rigter L<sup>1</sup>, van Harten WH<sup>1</sup>

<sup>1</sup>Netherlands Cancer Institute, Amsterdam, The Netherlands, <sup>2</sup>University of Washington and Panaxia bv, Seattle, WA, USA

**OBJECTIVES:** Evidence suggests that response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer patients. We estimated the expected cost-effectiveness and resource requirements of implementing RG-NACT with MRI vs. conventional-NACT for treatment of ER+/HER2- breast cancers in the Netherlands (NL). **METHODS:** A Markov-model was developed to analyse the incremental costs/QALY from a hospital perspective over a 5-year time horizon. Health services required (MRI scans performed, MRI technologists, breast radiologists and confirmatory scans) for and health outcomes (prevented relapses, prevented deaths, patients with adverse events or contraindications and MRI technologists with adverse events) of implementing RG-NACT were estimated via resource modelling analysis considering the current (4%) and a full implementation (100%) scenario in the Dutch population of ER+/HER2- breast cancer women (n=6306). **RESULTS:** RG-NACT is expected to generate 0.001 and 0.07 QALYs and save €8 and €341 costs for the 4% and 100% implementation scenarios respectively. At current implementation rate, 213 MRI examinations, 273 MRI technologists and 1 breast radiologist are required to prevent 0.4 relapses and 6 cancer deaths. At full implementation, a 25-fold increase in MRI examinations is projected, requiring ~5 times higher MRI utilization and 6560 additional MRI technologists, which is expected to prevent 10 additional relapses (+2400%) and 169 cancer deaths (+2400%). Increasing implementation rates markedly increased the number of confirmatory scans (+901), contraindications (+932) and MRI technologists experiencing adverse events (+1706) by 25-fold, and decreased the number of patients with adverse events (-29) by 1.3-fold. **CONCLUSIONS:** RG-NACT likely dominates conventional-NACT at current and full implementation rates. Full implementation generates a 25-fold increase in additional health benefits, but requires MRI capacity in the Netherlands to be increased 5-fold, which is challenging given a shortage of MRI technologists.

**PCN187**  
**ECONOMIC EVALUATION OF ORAL CHEMOTHERAPY REGIMEN IN METASTATIC**  
**BREAST CANCER EGYPTIAN PROSPECTIVE**

Abo Taleb AM<sup>1</sup>, Saad AS A<sup>2</sup>, Aboushady R<sup>3</sup>

<sup>1</sup>WHO, Cairo, Egypt, <sup>2</sup>Ain Shams University, Cairo, Egypt, <sup>3</sup>Central Administration for Pharmaceutical Affairs, Cairo, Egypt

**OBJECTIVES:** The main objective for conducting this study was to evaluate economic evaluation through the cost-effectiveness study of oral chemotherapy regimens we choose vinorelbine oral capsule plus oral capecitabine versus docetaxel iv plus oral capecitabine in treatment of metastatic breast cancer, in the Egyptian patients previously treated with anthracycline, from the national fund perspective over a time horizon of 3 years. **METHODS:** A cost-effectiveness analysis from the perspective of the Ministry of Health and Population was conducted. A Markov model was applied with three health states. Utility data were incorporated in the model to make adjusted results. Costs used were the local ones according to the national fund list. Discounting was applied at 3.5% annually both on costs and benefits. The results obtained were in term of ICER and number of QALYs. Robustness of our findings was checked using sensitivity analyses. Results are expressed in QALYs **RESULTS:** During the three-year time horizon, the total cost for oral chemotherapy regimen vinorelbine oral plus capsitabine was associated with a 2.46QALY gained. The total for docetaxel IV. was associated with 0.84 QALY gained. That yields a difference of and 1.62 in QALY. The oral chemotherapy regimen (Vinorelbine oral plus capsitabine is economically dominating the docetaxel strategy, producing more benefit at a lower cost. The one-dimensional sensitivity analysis indicated that the overall survival medians of both drugs had the largest impact on the results. When conducting sensitivity analysis using plausible ranges, Vinorelbine oral remained economically dominant in all cases. **CONCLUSIONS:** The introduction of oral chemotherapy regimen in metastatic breast cancer vinorelbine oral to the national fund Pay-at-The-Expense-of-the-State (PTES) system was likely be cost saving based strictly from its perspective.

**PCN188**  
**SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN**  
**HER2+ BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION**  
**ANALYSIS**

Nestorovska A<sup>1</sup>, Naumoska Z<sup>1</sup>, Grozdanova A<sup>1</sup>, Stoleski D<sup>2</sup>, Ivanovska A<sup>2</sup>, Risteski M<sup>3</sup>, Vasev N<sup>3</sup>, Ismaili I<sup>3</sup>, Stefanovski P<sup>4</sup>, Dimovski A<sup>1</sup>, Suturkova L<sup>1</sup>, Sterjev Z<sup>5</sup>

<sup>1</sup>ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia, <sup>2</sup>Roche Macedonia, DOOEL, Skopje, Macedonia, <sup>3</sup>University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, <sup>4</sup>Clinical Hospital, Bitola, Macedonia, <sup>5</sup>Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia

**OBJECTIVES:** The aim of this study is to compare the total cost of subcutaneous trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharmacokinetic profile and efficacy non-inferior to standard IV-TRA and is a valid alternative for the treatment of eligible breast cancer patients. **METHODS:** A cost-minimization analysis was performed using data from prior prospective time-motion study. Total time and cost of both types of TRA administration were quantified in a time horizon of over 18 cycles therapy course. The total of 169 patients (mean weight 74.20 kg) (300 observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and received the drug in the adjuvant (132 patients) or first line metastatic (37 patients) setting. Health care resources included drug treatment, patient's room and chair time treatments, active healthcare professional time and consumables. Non-health care resources encompassed patients' transport. The model accounted the 3% wastage of IV-TRA administration. Unit costs were obtained utilizing official (government and hospital pharmacy) publicly available data and they were expressed in Euro 2015, with no discount. **RESULTS:** Direct medical costs per (mean weight) patient were €30 500 for IV-TRA and €30 102 for SC-TRA. The mean total costs per patient of IV compared to SC administration of TRA over the full course of treatment were €30 695 and €30 106, respectively. SC-TRA incurred less non-drug related cost (€4,20) than IV-TRA (€196). The results of the model were most sensitive to patient weight and % of wastage in IV treated patients. Mean cost saving per patient over a full treatment course for SC administration was €589,2. Mean savings (preparation and administration) in time with SC-TRA were 47 min. **CONCLUSIONS:** SC-TRA can be time and cost-saving therapy for HER2+ breast cancer patients from the R. Macedonia.

**PCN189**  
**PHARMACOECONOMIC EVALUATION OF THE USE OF TRASTUZUMAB FOR**  
**SUBCUTANEOUS ADMINISTRATION COMPARED TO INTRAVENOUS DOSAGE**  
**FORM IN THE TREATMENT OF BREAST CANCER**

Kulikov A, Rybchenko Y

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**OBJECTIVES:** To determine the preferable treatment scheme for breast cancer (BC) from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) and intravenous (IV) administration. **METHODS:** The following pharmacoeconomic methods were used: cost-minimization analysis, budget impact analysis. **RESULTS:** For cost-minimization analysis the following costs were included: cost of testing on tumor expression of HER2, the main drug therapy, concomitant therapy (medical services and drugs), introduction, services provided by medical personnel and the conditions of administration (in case of hospitalization or outpatient). Total costs per 1 patient with BC for treatment course with trastuzumab for subcutaneous administration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastuzumab for IV administration. Cost-minimization analysis revealed treatment change from trastuzumab for IV administration on trastuzumab for SC administration gave economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According to budget impact analysis it was revealed that trastuzumab for SC administration allows to make economy of 175 508 955 RUB/2 919 796 EUR. **CONCLUSIONS:** During cost-minimization analysis it is determined that trastuzumab for IV allows to obtain economy compared with IV dosage form. Budget impact analysis reveals that change of BC treatment from trastuzumab for IV administration on trastuzumab for SC one give monetary economy.

**PCN190**  
**PHARMACOECONOMIC STUDY OF THE USE OF RITUXIMAB FOR SUBCUTANEOUS**  
**ADMINISTRATION IN THE TREATMENT OF FOLLICULAR LYMPHOMA**

Kulikov A, Rybchenko Y

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**OBJECTIVES:** To determine the most preferable from the pharmacoeconomic perspective treatment scheme of follicular lymphoma (FL) treatment with rituximab for subcutaneous (SC) and intravenous (IV) administration. **METHODS:** For this objective, the following pharmacoeconomic methods were used: cost-minimization analysis, budget impact. **RESULTS:** The following costs were calculated for cost-minimization analysis: the main drug therapy, concomitant therapy, including medical services and medicines, administration, services provided by medical personnel and the conditions of administration (outpatient or hospitalization). According to the cost analysis it was determined that cost of FL treatment equals 3 534 687 RUB/ 58 803 EUR under IV administration and 3 498 840 RUB/58 207 EUR under SC one. Cost-minimization analysis revealed that rituximab for SC administration compared with IV one gives economy of 35 847 RUB/ 596 EUR per one patient for treatment course. During budget impact analysis it was determined that rituximab for SC administration gives 177 083 678 RUB/ 2 945 994 EUR economy for treatment course of all patients in Russia. **CONCLUSIONS:** According to cost-minimization analysis, subcutaneous dosage form of rituximab allows to obtain economy compared with intravenous form. Budget impact analysis shows that rituximab for subcutaneous administration allows to make economy.

**PCN191**  
**COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY**  
**UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGUESE**  
**PATIENTS THAT ARE UNSUITABLE FOR FULL-DOSE FLUDARABINE BASED**  
**THERAPY**